Christel Renoux1,2,3, Ju-Young Shin1, Sophie Dell'Aniello1, Emma Fergusson4, Samy Suissa1,3. 1. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada. 2. Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada. 3. Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada. 4. The Clockhouse, Oxford Health, Oxford University, Oxford, UK.
Abstract
AIM: The aim of the present study was to describe the prescription of medications for attention-deficit hyperactivity disorder (ADHD) in the UK between 1995 and 2015. METHODS: Using the Clinical Practice Research Datalink (CPRD), we defined a cohort of all patients aged 6-45 years, registered with a general practitioner between January 1995 and September 2015. All prescriptions of methylphenidate, dexamphetamine/lisdexamphetamine and atomoxetine were identified and annual prescription rates of ADHD were estimated using Poisson regression. RESULTS: Within a cohort of 7 432 735 patients, we identified 698 148 prescriptions of ADHD medications during 41 171 528 person-years of follow-up. Usage was relatively low until 2000, during which the prescription rate was 42.7 [95% confidence interval (CI) 20.9, 87.2] prescriptions per 10 000 persons, increasing to 394.4 (95% CI 296.7, 524.2) in 2015, corresponding to an almost 800% increase (rate ratio 8.87; 95% CI 7.10, 11.09). The increase was seen in all age groups and in both sexes but was steepest in boys aged 10-14 years. The prescription rate in males was almost five times that of females. Methylphenidate remained the most prescribed drug during the 20-year study period, representing 88.9% of all prescriptions in the 6-24-year-old group, and 63.5% of all prescriptions in adults (25-45 years of age). CONCLUSIONS: Prescription rates of ADHD medications have increased dramatically in the past two decades. This may be due, at least in part, to both an increase in the number of patients diagnosed with ADHD over time and a higher percentage of those patients treated with medication.
AIM: The aim of the present study was to describe the prescription of medications for attention-deficit hyperactivity disorder (ADHD) in the UK between 1995 and 2015. METHODS: Using the Clinical Practice Research Datalink (CPRD), we defined a cohort of all patients aged 6-45 years, registered with a general practitioner between January 1995 and September 2015. All prescriptions of methylphenidate, dexamphetamine/lisdexamphetamine and atomoxetine were identified and annual prescription rates of ADHD were estimated using Poisson regression. RESULTS: Within a cohort of 7 432 735 patients, we identified 698 148 prescriptions of ADHD medications during 41 171 528 person-years of follow-up. Usage was relatively low until 2000, during which the prescription rate was 42.7 [95% confidence interval (CI) 20.9, 87.2] prescriptions per 10 000 persons, increasing to 394.4 (95% CI 296.7, 524.2) in 2015, corresponding to an almost 800% increase (rate ratio 8.87; 95% CI 7.10, 11.09). The increase was seen in all age groups and in both sexes but was steepest in boys aged 10-14 years. The prescription rate in males was almost five times that of females. Methylphenidate remained the most prescribed drug during the 20-year study period, representing 88.9% of all prescriptions in the 6-24-year-old group, and 63.5% of all prescriptions in adults (25-45 years of age). CONCLUSIONS: Prescription rates of ADHD medications have increased dramatically in the past two decades. This may be due, at least in part, to both an increase in the number of patients diagnosed with ADHD over time and a higher percentage of those patients treated with medication.
Authors: Guilherme Polanczyk; Maurício Silva de Lima; Bernardo Lessa Horta; Joseph Biederman; Luis Augusto Rohde Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Carlos Treceño; Luis H Martín Arias; Maria Sáinz; Inés Salado; Pilar García Ortega; Veronica Velasco; Natalia Jimeno; Antonio Escudero; Alfonso Velasco; Alfonso Carvajal Journal: Pharmacoepidemiol Drug Saf Date: 2012-01-17 Impact factor: 2.890
Authors: Susanna N Visser; Melissa L Danielson; Rebecca H Bitsko; Joseph R Holbrook; Michael D Kogan; Reem M Ghandour; Ruth Perou; Stephen J Blumberg Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-11-21 Impact factor: 8.829
Authors: Suzanne McCarthy; Lynda Wilton; Macey L Murray; Paul Hodgkins; Philip Asherson; Ian C K Wong Journal: BMC Pediatr Date: 2012-06-19 Impact factor: 2.125
Authors: Helen-Maria Vasiliadis; Fatoumata Binta Diallo; Louis Rochette; Mark Smith; Donald Langille; Elizabeth Lin; Steve Kisely; Eric Fombonne; Angus H Thompson; Johanne Renaud; Alain Lesage Journal: Can J Psychiatry Date: 2017-06-15 Impact factor: 4.356
Authors: Krista F Huybrechts; Gabriella Bröms; Lotte Brix Christensen; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Sonia Hernandez-Diaz; Pär Karlsson; Øystein Karlstad; Helle Kieler; Anna-Maria Lahesmaa-Korpinen; Helen Mogun; Mette Nørgaard; Johan Reutfors; Henrik Toft Sørensen; Helga Zoega; Brian T Bateman Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Alfredo H Cía; Juan Carlos Stagnaro; Sergio Aguilar Gaxiola; Horacio Vommaro; Gustavo Loera; María Elena Medina-Mora; Sebastían Sustas; Corina Benjet; Ronald C Kessler Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2018-02-19 Impact factor: 4.328